Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines.

被引：0
|
作者：
Filipits, Martin
Dubsky, Peter Christian
Rudas, Margaretha
Brase, Jan C.
Kronenwett, Ralf
Weber, Karsten E.
Petry, Christoph
Schmidt, Marcus
Luisser, Irmard
Klug, Evelyn
Gnant, Michael
机构：
[1] Med Univ Vienna, Ctr Comprehens Canc, Inst Canc Res, Vienna, Austria
[2] Med Univ Vienna, Dept Surg, Vienna, Austria
[3] Med Univ Vienna, Dept Pathol, Vienna, Austria
[4] Sividon Diagnost GmbH, Cologne, Germany
[5] Johannes Gutenberg Univ Mainz, Dept Obstet & Gynecol, D-55122 Mainz, Germany
[6] Gussing Hosp, Dept Surg, Gussing, Austria
[7] Oberwart Hosp, Dept Pathol, Oberwart, Austria
[8] Med Univ Vienna, Ctr Comprehens Canc, Dept Surg, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
542
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prospective comparison of uPA/PAI-1 and EndoPredict-clin score in ER-positive, HER2-negative breast cancer: impact on risk stratification and treatment decisions
    Etti, Johannes
    Lackmann, Kirsten Grosse
    Hapfelmeier, Alexander
    Klein, Evelyn
    Paepke, Stefan
    Petry, Christoph
    Specht, Katja
    Hoefier, Heinz
    Kiechle, Marion
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer
    Jung, Wonguen
    Kim, Kyubo
    Moon, Byung-In
    [J]. BREAST CARE, 2022, 17 (06) : 561 - 566
  • [3] The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer.
    Brase, J. C.
    Gehrmann, M. C.
    Petry, C.
    Weber, K. E.
    Schmidt, M.
    Koelbl, H.
    Brauch, H.
    Schwab, M.
    Mueller, V.
    Jaenicke, F.
    Rody, A.
    Kaufmann, M.
    Filipits, M.
    Gnant, M.
    Denkert, C.
    Loibl, S.
    von Minckwitz, G.
    Kronenwett, R.
    [J]. CANCER RESEARCH, 2011, 71
  • [4] EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
    Dubsky, P.
    Filipits, M.
    Jakesz, R.
    Rudas, M.
    Singer, C. F.
    Greil, R.
    Dietze, O.
    Luisser, I.
    Klug, E.
    Sedivy, R.
    Bachner, M.
    Mayr, D.
    Schmidt, M.
    Gehrmann, M. C.
    Petry, C.
    Weber, K. E.
    Kronenwett, R.
    Brase, J. C.
    Gnant, M.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (03) : 640 - 647
  • [5] Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
    Pelaez-Garcia, Alberto
    Yebenes, Laura
    Berjon, Alberto
    Angulo, Antonia
    Zamora, Pilar
    Sanchez-Mendez, Jose Ignacio
    Espinosa, Enrique
    Redondo, Andres
    Heredia-Soto, Victoria
    Mendiola, Marta
    Feliu, Jaime
    Hardisson, David
    [J]. PLOS ONE, 2017, 12 (09):
  • [6] Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
    Constantinidou, Anastasia
    Marcou, Yiola
    Toss, Michael S.
    Simmons, Timothy
    Bernhisel, Ryan
    Hughes, Elisha
    Probst, Braden
    Meek, Stephanie
    Kakouri, Eleni
    Georgiou, Georgios
    Zouvani, Ioanna
    Savvidou, Gabriella
    Kuhl, Vanessa
    Doedt, Jennifer
    Wagner, Susanne
    Gutin, Alexander
    Slavin, Thomas P.
    Lanchbury, Jerry S.
    Kronenwett, Ralf
    Ellas, Ian O.
    Rakha, Emad A.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (20) : 4435 - 4443
  • [7] The impact of intratumoral heterogeneity on the prognosis of ER-positive/HER2-negative breast cancer
    Oikawa, Masahiro
    Ishida, Mayumi
    Nakamura, Yoshiaki
    Nishimura, Sumiko
    Koga, Chinami
    Saruwatari, Akihiro
    Igawa, Akiko
    Akiyoshi, Sayuri
    Koi, Yumiko
    Ohno, Shinji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer
    Hageman, Elizabeth
    Lussier, Mia E.
    [J]. ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 849 - 856
  • [9] Elacestrant in advanced ER-positive, HER2-negative breast cancer
    Kuenzell, Judith Lorenz
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (01) : 16 - 16
  • [10] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Christopher D. Hart
    Ilenia Migliaccio
    Luca Malorni
    Cristina Guarducci
    Laura Biganzoli
    Angelo Di Leo
    [J]. Nature Reviews Clinical Oncology, 2015, 12 : 541 - 552
12345